919116-36-2

Basic information

• Product Name: 4-chloro-2-(Methylthio)-5-(trifluoroMethyl)pyriMidine
• Synonyms: 4-chloro-2-(Methylthio)-5-(trifluoroMethyl)pyriMidine;Pyrimidine,4-chloro-2-(methylthio)-5-(trifluoromethyl)-;4-Chloro-2-methylsulfanyl-5-(trifluoromethyl)pyrimidine
• CAS NO: 919116-36-2
• Molecular Formula: C₆H₄ClF₃N₂S
• Molecular Weight: 228.6225696
• Mol File: 919116-36-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-chloro-2-(Methylthio)-5-(trifluoroMethyl)pyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-2-(Methylthio)-5-(trifluoroMethyl)pyriMidine(919116-36-2)
• EPA Substance Registry System: 4-chloro-2-(Methylthio)-5-(trifluoroMethyl)pyriMidine(919116-36-2)

Safety Data

• Hazardous Substances Data: 919116-36-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-chloro-2-(Methylthio)-5-(trifluoroMethyl)pyriMidine is used as an intermediate in the synthesis of pharmaceuticals for its potential pharmacological activities, such as its antifungal and anti-tumor properties.
Used in Agrochemical Industry:
4-chloro-2-(Methylthio)-5-(trifluoroMethyl)pyriMidine serves as a building block in the production of herbicides and pesticides, contributing to the development of effective agricultural solutions.
Used in Research:
4-chloro-2-(Methylthio)-5-(trifluoroMethyl)pyriMidine is utilized in research settings to explore its potential applications and properties, further expanding its use in both industrial and pharmaceutical domains.

Upstream product

• 3932-97-6 2,4-dichloro-5-trifluoromethylpyrimidine 
• 5188-07-8 sodium thiomethoxide 

Relevant articles and documents

HETEROCYCLIC COMPOUND

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF

Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.

HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF

Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers. (I)

AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF

Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).

COMPOUND, COMPOSITIONS, AND METHODS

Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF

The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or lnterleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.

FAK AND FLT3 INHIBITORS

The use of a compound of the formula (I): (Formula (I)) in the preparation of a medicament for treating Acute Myeloid Leukemia or a disease ameliorated by the inhibition of Flt3, or Flt3 and FAK.

FAK INHIBITORS

A compound of the formula (I): where R1 or R2 is a cycle amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.